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INTRODUCTION
Osteoarthritis (OA) is a painful disease that affects approxi-
mately 10% of adults above 60 years of age.1 OA is character-
ized by synovitis, chondrocyte apoptosis, and inflammation, 
resulting in the destruction of articular cartilage. Apart from 
these characteristics, chondrocytes can respond to external 
stimuli and tissue damage and are responsible for OA.2 Chon-
drocytes in articular cartilage tissue play a pivotal role in main-
taining tissue health by secreting extracellular matrix (ECM) 
proteins.3 Chondrocyte dysfunction leads to matrix proteinase 
activation4 and the degradation of the ECM,5 resulting in the 
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deterioration of cartilage integrity and the development of OA. 
In an OA environment, chondrocytes undergo physiological 
changes and secrete proteolytic enzymes, such as MMP136 or 
ADAMTS5,7 that, in turn, cause damage to the cartilage tissue, 
leading to joint dysfunction.8 Therefore, it is important to un-
derstand the changes in chondrocyte behavior in an osteoar-
thritic environment in order to establish a successful strategy 
for OA therapy.
Investigation of genes involved in OA pathogenesis can pro-
vide molecular insights, and related genes can be considered 
as candidates with which to identify novel therapeutic targets 
for treating OA. In particular, non-coding RNAs (ncRNAs) are 
excellent targets for OA gene therapy since they do not encode 
proteins, and thus, targeting ncRNAs may have fewer unexpect-
ed side effects than targeting protein-coding genes.9 ncRNAs 
are classified based on their transcript length: small ncRNAs are 
less than 200 nucleotides and long non-coding RNAs are more 
than 200 nucleotides. MicroRNAs (miRNAs) are a class of small 
ncRNAs that inhibit mRNA translation of target genes by bind-
ing to the 3'-untranslated region (UTR) of target mRNAs. miR-
NAs play a role in multiple cellular functions and can have mul-
tiple targets, and a single gene can be regulated by multiple 
miRNAs.10 To date, many miRNAs have been described as novel 
targets for OA therapy and are anticipated to be of use as bio-
markers for the diagnosis and prognosis of OA.11 
In this study, we aimed to evaluate the effects of anti-miR-495 
on immortalized human chondrocyte cells (TC28a2 cells) un-
der inflammatory conditions. Our previous study demonstrat-
ed that introduction of anti-miR-495 improved the differentia-
tion potential of the chondrogenic lineage among mesenchymal 
stem cells (MSCs) by disrupting the binding between miR-
NA-495 and the 3'-UTR of SOX9 mRNA.12 Recent studies have 
shown that miRNA-495 is involved in chondrocyte apoptosis 
by regulating the apoptotic signaling pathways, such as AKT/
mTOR and NF-κB.13,14 These studies have also indicated that 
miRNA-495 is highly expressed in the cartilage of rats with OA, 
compared with rats in sham groups. Therefore, it might be 
meaningful to investigate whether miRNA-495 could be a novel 
target molecule for OA therapeutics. In the current study, we 
showed that miRNA-495 is upregulated in interleukin-1β (IL-
1β)-treated TC28a2 cells and primary-cultured chondrocytes 
obtained from damaged cartilage tissues of patients with OA. 
Transfection of anti-miR-495 into IL-1β-treated TC28a2 cells 
decreased the upregulation of inflammatory markers and res-
cued reductions in chondrocyte marker levels. We also exam-
ined the protein levels of miRNA-495 targets, such as SOX9 
and CCL4, in the cartilage tissues of patients with OA. We ob-
served that the anti-miR-495-mediated prophylactic effects on 
OA in vitro were dependent on the presence of SOX9. Based 
on these results, we suggest that miRNA-495 may be a valuable 
target for designing novel therapies for OA treatment.
MATERIALS AND METHODS
Cell culture
The TC28a2 normal human chondrocyte cell line was pur-
chased from Sigma-Aldrich (St. Louis, MO, USA). Human pri-
mary chondrocytes were obtained from articular cartilage tis-
sues from the knee joints of patients with OA with approval 
from the Institutional Review Board (IRB) (2019-1374-002) of 
Yonsei University College of Medicine. The cartilage tissue 
was divided into two groups to separate the chondrocytes: the 
site of intact tissues and the site of damaged tissues. The tissues 
were thoroughly minced and subsequently digested with 0.1% 
collagenase type II (Sigma-Aldrich) for 6 h. TC28a2 cells and 
primary chondrocytes were maintained in Dulbecco’s modified 
Eagle’s medium with high glucose (DMEM-HG; Gibco, Carls-
bad, CA, USA) containing 10% fetal bovine serum (FBS; Gibco) 
and 1% (v/v) antibiotic antimycotic solution (Gibco) at 37°C 
and 5% CO2. 
Monolayer micromass culture and IL-1β treatment
To mimic the OA environment in in vitro cell culture condi-
tions, TC28a2 cells were seeded in the center of the individual 
wells of 24-well plates at 1×105 cells per well in a 10-μL volume. 
The cells were then allowed to adhere for 2 h in a cell culture in-
cubator. Next, DMEM-HG supplemented with 1% insulin trans-
ferrin selenium-A (ITS-A; Invitrogen, Carlsbad, CA, USA) was 
added gently. IL-1β (R&D Systems, Minneapolis, MN, USA) 
was chosen to induce and maintain inflammatory conditions, 
and the concentration of IL-1β was 10 ng/mL, based on our pre-
vious results.15 The cells were maintained for 5 d in the absence 
or presence of IL-1β and stained with 1% safranin O (Sigma) so-
lution to visualize proteoglycan content produced by the chon-
drocytes. Crystal violet (CV; Merck, Darmstadt, Germany) stain-
ing was performed to compare the density of the cells stained 
by safranin O. The CV staining method has been described pre-
viously.16 For quantitative analysis, absorbance was detected at 
490 nm after destaining with 50% acetic acid solution for 20 
min. Each safranin O value was normalized to absorbance from 
CV staining.
Quantitative real-time polymerase chain reaction 
Total RNA was isolated from cells using TRIzol reagent (Invitro-
gen). For cDNA synthesis, 1 µg of RNA was reverse-transcribed 
using the Mir-XTM miRNA First-Strand Synthesis Kit (Takara 
Bio, San Jose, CA, USA) and AccuPrep Universal RNA Extrac-
tion Kit (Bioneer, Daejeon, South Korea). Quantitative real-time 
polymerase chain reaction (qRT-PCR) was performed using 
the StepOnePlus Real-Time PCR System (Applied Biosystems, 
Foster City, CA, USA) and 2xqPCRBIO SyGreen Mix (PB20.12-
05, PCR Biosystems, London, UK) according to the manufac-
turer’s instructions. The primer sequences are listed in Table 1. 
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Western blot analysis
Total proteins were isolated from the cells using PRO-PREPTM 
Protein Extraction Solution (iNtRON Biotechnology, Seong-
nam, South Korea). Protein concentrations were determined 
using the Bio-Rad protein assay kit (Bio-Rad Laboratories, Inc., 
Hercules, CA, USA). Protein samples (10 to 30 μg of each sam-
ple) were separated by sodium dodecyl sulfate polyacrylamide 
gel electrophoresis and then transferred onto polyvinylidene 
difluoride membranes. The membranes were blocked with 
tris-buffered saline with Tween 20 (TBST) containing 5% skim 
milk (BD Biosciences, Sparks, MD, USA), and subsequently 
incubated overnight at 4°C with primary antibodies against 
SOX9 (1:1000, sc-166505; Santa Cruz Biotechnology, Santa 
Cruz, CA, USA), CCL4 (1:1000, sc-393441; Santa Cruz Biotech-
nology), β-actin (1:1000, sc-47778; Santa Cruz Biotechnology), 
COL2A1 (1:1000, sc-518017; Santa Cruz Biotechnology), COX-
2 (1:1000, 610203; BD Biosciences), MMP13 (1:1000, 69926; 
Cell Signaling Technology, Danvers, MA, USA), and ADAMTS5 
(1:1000, PA5-27165; Invitrogen). All membranes were washed 
three times with TBST for 10 min and incubated with horse-
radish peroxidase (HRP)-conjugated secondary antibodies 
(1:5000, SA001-500 or SA002-500, GenDEPOT, Barker, TX, USA) 
for 1 h. Finally, all the membranes were washed three times 
with TBST for 10 min, and the blots were imaged using the LAS 
4000 imaging system (Fujifilm, Tokyo, Japan).
Glycosaminoglycan content assay
The amount of sulfated glycosaminoglycans (GAGs) was de-
termined in the culture medium obtained from TC28a2 cells 
cultured for 5 d using the Blyscan kit (Biocolor, County Antrim, 
UK) according to the manufacturer’s instructions. In brief, 
500 μL of the culture medium was mixed with 1 mL of Blyscan 
dye reagent by shaking for 30 min to complete GAG–dye bind-
ing. After centrifugation, the dye bound to GAGs was dissolved 
in a dissociation reagent. The concentration of the recovered 
dye was determined at 656 nm, and chondroitin 4-sulfate stan-
dard solution (Biocolor) was used to generate standard curves. 
All samples and standards were tested in triplicate.
Anti-miRNA and siRNA transfection
TC28a2 cells were seeded at a density of 2×105 cells per well in 
6-well plates. After 24 h of culture, cells were transfected with 
negative control anti-miRNA (50 nM), anti-miR-495 (50 nM), 
negative control siRNA (200 nM), SOX9 siRNA (200 nM), or 
CCL4 siRNA (200 nM) using CalFectin (Signagen Laborato-
ries, Rockville, MD, USA) according to the manufacturer’s in-
structions. All constructs were purchased from Bioneer (Dae-
jeon, South Korea). The anti-miRNA and siRNA sequences are 
listed in Table 2.
Immunohistochemistry
Human cartilage tissue sections were fixed in 10% formalin at 
room temperature for 7 days. After fixation, the formalin-fixed 
specimens were embedded in paraffin. The paraffin-embed-
ded sections were deparaffinized, rehydrated, and washed 
with phosphate-buffered saline, and the tissue sections were 
evaluated for the disruption of cartilage tissue in the human car-
tilage. The prepared tissue samples were sliced to a thickness of 
4 mm and stained using safranin O solution to observe the pro-
gression of OA, or were incubated with anti-SOX9 (Santa Cruz 
Biotechnology) or anti-CCL4 (Santa Cruz Biotechnology) an-
tibodies to detect SOX9 and CCL4 levels. The signals were de-
tected using the AEC substrate kit (Abcam, Cambridge, UK). 
The stained tissue sections were observed using a VS120 virtual 
microscope (Olympus, Tokyo, Japan), and images were ana-
lyzed using the OlyVIA 2.5 program (Olympus).
Statistical analysis
All experiments were performed in triplicate using samples 
from at least three donors. Student’s t-test was used to assess the 
significance of statistical differences for two-group compari-
sons. The significance of the statistical differences between 
three or more groups was calculated using one-way analysis of 
variance and post hoc Bonferroni correction. Data are present-
ed as a mean±standard deviation. For all tests, results with p< 
0.05 were considered statistically significant.
Table 2. Anti-miRNA and siRNA Sequences Used in This Study







AAA CAA ACA UGG UGC ACU UCU U 
Reverse
SOX9 siRNA
Forward CUC GUA CCC AAA UUU CCA A=tt
Reverse UUG GAA AUU UGG GUA CGA G=tt
CCL4 siRNA
Forward GCU GAU CCC AGU GAA UCC U=tt
Reverse AGG AUU CAC UGG GAU CAG C=tt
Table 1. Primer Sequences Used in this Study
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RESULTS
Osteoarthritic environment upregulates miRNA-495 
expression in chondrocytes
We first sought to mimic the OA environment in a cell culture 
model to evaluate the expression levels of miRNA-495. IL-1β 
and TC28a2 cells were used to mimic OA under in vitro cell 
culture conditions. TC28a2 cells were treated with 10 ng/mL of 
IL-1β daily, and the cells were maintained for 5 days. Safranin 
O staining was performed to confirm the effect of IL-1β on in-
hibiting the synthesis of proteoglycans produced by chondro-
cytes. Compared with the control group, IL-1β-treated cells 
showed weaker safranin O staining intensity (Fig. 1A). The 
mRNA levels of contributors to cartilage matrix protein deple-
tion, such as prostaglandin E synthase (PTGES), a disintegrin 
and metalloproteinase with thrombospondin motifs 5 (AD-
AMTS5), and matrix metalloproteinase 13 (MMP13), were 
strongly upregulated by IL-1β treatment (Fig. 1B). The protein 
levels of cyclooxygenase-2 (COX-2), ADAMTS5, and MMP13 
were also upregulated upon IL-1β treatment in a time-depen-
dent manner. Meanwhile, however, the protein levels of chon-
drogenic markers, such as SOX9 and COL2A1, gradually de-
creased (Fig. 1C). The mRNA levels of SOX9 and COL2A1 were 
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Fig. 1. miRNA-495 is upregulated during osteoarthritis progression in an in vitro model generated using the human normal chondrocyte cell line 
TC28a2. (A) TC28a2 cells were seeded at 1×105 cells per well in 24-well culture plates. The cells were treated with 10 ng/mL of IL-1β or with no IL-1β 
as a control. Safranin O staining was performed to detect glycosaminoglycans (GAGs). Stained cells were destained with 10% cetylpyridinium for 
quantitative analysis. Absorbance was measured at 490 nm. *p<0.05 compared to the control groups (n=3 experimental replicates). (B) The graphs 
represent the results of quantitative real-time polymerase chain reaction (qRT-PCR) using RNA extracted from TC28a2 cells that were treated with 10 
ng/mL of IL-1β or with no IL-1β as a control (n=3 experimental replicates). The expression levels of all transcripts tested were normalized to those of 
18S rRNA. The data are presented as means±SD. *p<0.05 compared to the IL-1β (-) groups. (C) Protein levels of SOX9, COL2A1, COX-2, ADAMTS5, 
and MMP13 were analyzed in TC28a2 cells using Western blotting, and the proteins were isolated on days 0, 1, 3, and 5 after treatment with 10 ng/mL 
of IL-1β. The graphs represent the average values of band intensity for each blot, and each blot was normalized to the band intensity value of β-actin 
(n=3 experimental replicates). The data are presented as means±SD [COX-2 (*p<0.05 vs. Day 1), ADAMTS5 (*p<0.05 vs. Day 3), SOX9 and COL2A1 
(*p<0.05 vs. Day 0)]. (D) The graphs represent the results of qRT-PCR using RNA extracted from TC28a2 cells treated with 10 ng/mL of IL-1β or with no 
IL-1β as a control (n=3 experimental replicates). The expression levels of miR-495 were normalized to those of U6. The data are presented as 
means±SD. *p<0.05 vs. Day 0. IL-1β, interleukin-1β; SFO, safranin O; CV, crystal violet; ND, not detectable.
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induced inflammatory conditions, which might be due to the 
roles of collagenases, such as MMP13 and ADAMTS5, at the 
post-translational level.17-19 Based on these results, we con-
firmed the successful mimicking of the OA environment in vitro 
using TC28a2 cells. Further, to determine whether the expres-
sion levels of miRNA-495 are altered in the in vitro OA environ-
ment, TC28a2 cells were treated with IL-1β for 5 days, and a 
change in the expression of miRNA-495 was observed through 
qRT-PCR. The results showed that the expression levels of miR-
NA-495 gradually increased upon treatment with IL-1β (Fig. 
1D). These results indicated that upregulation of miRNA-495 
may be involved in OA pathogenesis under IL-1β-mediated in-
flammatory conditions.
Anti-miR-495 attenuates IL-1β-mediated OA 
progression in vitro
To determine whether the upregulation of miRNA-495 is in-
volved in IL-1β-mediated OA progression in vitro, anti-miR-495 
(hsa-miR-495-3p) was used to suppress the upregulation of 
miRNA-495 upon IL-1β treatment in TC28a2 cells. Our previous 
study showed that miRNA-495 binds to the 3'-UTR of SOX9 
mRNA and inhibits its expression.12 Based on this previous 
study, the dose and effectiveness of anti-miR-495 were deter-
mined according to changes in SOX9 protein levels (Fig. 2A). 
Transfection with anti-miR-495 protected TC28a2 cells against 
IL-1β-mediated loss of proteoglycans, as observed by safranin 
O staining (Fig. 2B), indicating that miRNA-495 is involved in 
the degradation of matrix proteins by chondrocytes. The results 
of the GAG content assays also showed that upon anti-miR-495 
transfection, chondrocytes retained the ability to produce GAGs 
even in the presence of IL-1β (Fig. 2C). As expected, the protein 
levels of SOX9 and COL2A1, which were downregulated by IL-
1β, were rescued in the anti-miR-495-transfected group, while 
the protein levels of MMP13 and ADAMTS5, which were up-
regulated by IL-1β, were reduced in the anti-miR-495-trans-
fected group (Fig. 2D). However, anti-miR-495 did not affect 
Fig. 2. Inhibition of miRNA-495 expression during in vitro osteoarthritis progression protects chondrocytes from IL-1β-mediated disruption of SOX9 
and COL2A1. (A) Protein levels of SOX9 were analyzed in TC28a2 cells transfected with anti-miR negative control (NC, 100 nM), anti-miR-495 (50 or 100 
nM) by Western blotting to determine the effective dose of anti-miR-495. (B) TC28a2 cells transfected with anti-miR NC (50 nM) or anti-miR-495 (50 
nM) were seeded at 1×105 cells per well in 24-well culture plates. The cells were treated with 10 ng/mL of IL-1β or with no IL-1β as a control. Safranin 
O staining was performed to detect glycosaminoglycans (GAGs). Stained cells were destained with 10% cetylpyridinium for quantitative analysis. Ab-
sorbance was measured at 490 nm. *p<0.05 compared to Group 2 (n=3 experimental replicates). (C) GAG content was measured using the Blyscan 
sulfate GAG assay. The sulfated GAGs were quantified in the supernatant and standardized using the chondroitin 4-sulfate standard solution. *p<0.05 
compared to group 2 (n=3 experimental replicates). (D) Protein levels of SOX9, COL2A1, COX-2, ADAMTS5, and MMP13 were analyzed in 10 ng/mL of 
IL-1β-treated TC28a2 cells transfected with anti-miR NC (50 nM) or anti-miR-495 (50 nM) using Western blotting. The graphs represent the average 
values of the band intensity for each blot, and each blot was normalized to the band intensity value of β-actin (n=3 experimental replicates). The data 























































1  2  3 1  2  3 1  2  3 1  2  3 1  2  3
Groups Groups Groups















1     2     3














































 Anti-miR NC (50 nM) + + -
 Anti-miR-495 (50 nM) - - +
 IL-1β (10 ng/mL) - + +
 Anti-miR NC (50 nM) + + -
 Anti-miR-495 (50 nM) - - +
 IL-1β (10 ng/mL) - + +
 Anti-miR NC (nM) 100 - -







Soyeong Joung, et al.
https://doi.org/10.3349/ymj.2021.62.7.650
the protein levels of COX-2, indicating that IL-1β-mediated 
upregulation of miRNA-495 is independent of COX-2 expres-
sion. Accordingly, these data suggest that miRNA-495 could 
be a target for the treatment of OA, and the anti-miR-495-me-
diated inhibitory effect of COL2A1 degradation in the presence 
of IL-1β may depend on the rescue effect of SOX9.
Reduced SOX9 expression is associated with OA 
progression
miRNA-495 has been shown to be involved in various devel-
opmental and inflammatory processes, as well as in the devel-
opment of normal or tumor cells.20 Importantly, it has been 
shown that miRNA-495 targets chemokine ligand 4 (CCL4) to 
repress the activity of nuclear factor kappa light chain enhanc-
er of activated B cells (NF-κB) in chondrocytes.14 The study sug-
gested that inhibition of miRNA-495 prevents chondrocyte 
apoptosis and enhances their proliferation through upregula-
tion of CCL4 in the OA environment. Since CCL4 is known as a 
mediator of IL-1β-mediated inflammation in chondrocytes,21 
it is possible that targeting miRNA-495 may increase the inflam-
matory response in chondrocytes. In the current study, we ob-
served that miRNA-495 is upregulated in chondrocytes treat-
ed with IL-1β (Fig. 1D). In addition, the inhibition of miRNA-495 
clearly prevented IL-1β-mediated inflammation (Fig. 2). To ad-
dress this paradoxical mechanism, we first checked the mRNA 
levels of the targets of miRNA-495, SOX9, and CCL4, in chon-
drocytes derived from patients with OA. The mRNA levels of 





































































































































































































































































































Human cartilage tissues from OA patients





Fig. 3. Contradictory expression levels of SOX9 and CCL4 in damaged cartilage tissues obtained from patients with osteoarthritis (OA). (A) The graphs 
present the results of quantitative real-time polymerase chain reaction (qRT-PCR) using RNA extracted from primary chondrocytes isolated from the 
intact or damaged parts of the cartilage tissues from patients with OA. The expression levels of SOX9 and CCL4 mRNAs were normalized to those of 
18S rRNA. The data are presented as means±SD. *p<0.05 compared to each intact control group (Damaged-1 vs. Intact-1, Damaged-2 vs. Intact-2, or 
Damaged-3 vs. Intact-3; n=3 experimental replicates). The number specified for each letter in the bar graphs means that the tissue was obtained from 
the same patient. For example, “Intact-1” and “Damaged-1” mean that the cartilage tissue obtained from the same patient was divided into "Intact" 
and "Damaged" parts and then chondrocytes were isolated from each divided tissue. (B) Protein levels of SOX9 and CCL4 were analyzed in primary 
chondrocytes isolated from the intact or damaged parts of the cartilage tissues from patients with OA using Western blotting. The graphs present the 
average values of the band intensity for each blot, and each blot was normalized to the band intensity value of β-actin. The data are presented as 
means±SD. *p<0.05 vs. Intact sample (n=3 experimental replicates). (C) Representative images of SOX9 and CCL4 immunostaining and safranin O 
staining in intact and damaged cartilage tissues from patients with OA. Scale bar=200 μm. (D) Quantification of SOX9- or CCL4-positive cells from total 
cell population per field in immunostained sections. The data are presented as means±SD. *p<0.05 vs. Intact sample (n=3 experimental replicates). (E) 
The graphs represent the results of qRT-PCR using RNA extracted from primary chondrocytes isolated from the intact or damaged parts of the carti-
lage tissues from patients with OA. The expression levels of miR-495 were normalized to those of U6. The data are presented as means±SD. *p<0.05 
compared to each intact control group (Damaged-1 vs. Intact-1, Damaged-2 vs. Intact-2, or Damaged-3 vs. Intact-3; n=3 experimental replicates). The 
number specified for each letter in bar graphs means that the tissue was obtained from the same patient.
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damaged cartilage tissues of patients with OA, while the mRNA 
levels of CCL4 were upregulated (Fig. 3A). Likewise, the pro-
tein levels of SOX9 and CCL4 were also increased, similar to 
their mRNA expression (Fig. 3B). For histological analysis, saf-
ranin O staining and immunohistochemistry were performed 
using cartilage tissues obtained from patients with OA. The re-
sults showed that SOX9 was present mostly in intact cartilage 
tissues and undetectable in damaged cartilage tissues. CCL4 
was detected more in damaged cartilage than in the cartilage 
(Fig. 3C and D). To confirm if this result was clinically mean-
ingful, we checked the levels of miRNA-495 in human OA pa-
tient-derived chondrocytes as well. Chondrocytes were isolat-
ed from intact or damaged cartilage tissues of patients with OA, 
and the cells were separated into two groups. miRNA-495 was 
highly upregulated in chondrocytes isolated from damaged car-
tilage tissues (Fig. 3E). These results indicated that SOX9, rather 
than CCL4, is more strongly correlated with miRNA-495, 
whose expression was increased in the OA environment.
miRNA-495-mediated SOX9 regulation is the target 
axis for anti-miR-495 in the OA environment
To address the importance of SOX9 or CCL4 in an in vitro OA 
environment regulated by miRNA-495, we performed an RNA 
knockdown study and confirmed that 200 nM of siRNA was 
effective in downregulating the mRNA levels of SOX9 or CCL4 
(Fig. 4A). The results of safranin O staining and GAG content 
assays showed that the anti-miR-495-mediated rescue effect in 
IL-1β-treated chondrocytes was completely abolished by SOX9 
knockdown, while knockdown of CCL4 did not have any effect 
(Fig. 4B and C). While transfection with anti-miR-495 rescued 
the protein levels of COL2A1 in IL-1β-treated cells, knockdown 
of SOX9 completely abolished the rescue effect of anti-miR-495. 
Fig. 4. miRNA-495–SOX9 axis is more important than miRNA-495–CCL4 axis in protecting chondrocytes against IL-1β-mediated inflammation. (A) The 
graphs represent the results of quantitative real-time polymerase chain reaction (qRT-PCR) using RNA extracted from TC28a2 cells transfected with 
negative control (NC) siRNA (200 nM), SOX9 siRNA (100 or 200 nM), or CCL4 siRNA (100 or 200 nM) (n=3 experimental replicates) to validate the effi-
ciency of the siRNAs used in this study. The expression levels of SOX9 and CCL4 mRNAs were normalized to those of 18S rRNA. The data are pre-
sented as means±SD. *p<0.05 compared to the 200 nM of NC siRNA groups. (B) Anti-miR-NC- or anti-miR-495-transfected TC28a2 cells were co-trans-
fected with NC siRNA, SOX9 siRNA, or CCL4 siRNA, and then the cells were seeded at 1×105 cells per well in 24-well culture plates. The cells were 
treated with 10 ng/mL of IL-1β or with no IL-1β as a control. Safranin O staining was performed to detect glycosaminoglycans (GAGs). Stained cells 
were destained with 10% cetylpyridinium for quantitative analysis. Absorbance was measured at 490 nm. *p<0.05 for comparison between two groups 
(n=3 experimental replicates). (C) GAG content was measured using the Blyscan sulfate GAG assay. The sulfated GAGs were quantified in the super-
natant and standardized using the chondroitin 4-sulfate standard solution. *p<0.05 compared to group 1 or 3 (n=3 experimental replicates). (D) Protein 
levels of SOX9, COL2A1, COX-2, ADAMTS5, and MMP13 were analyzed in the cells using Western blotting. The graphs represent the average value 
of the band intensity for each blot, and each blot was normalized to the band intensity value of β-actin. The data are presented as means±SD. *p<0.05 
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 Anti-miR-495 (50 nM) - - + + +
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Protein levels of MMP13 and ADAMTS5 were also dependent 
on the presence of SOX9 in anti-miR-495-transfected cells. 
However, CCL4 knockdown did not have any effect in IL-1β-
treated TC28a2 cells transfected with anti-miR-495 (Fig. 4D). 
These results indicated that SOX9 is a crucial mediator of anti-
miR-495-mediated therapeutic effects in OA treatment. Taken 
together, these results suggest that miRNA-495-mediated re-
duction of SOX9 expression contributes to OA pathogenesis, 
and therefore, the miRNA-495–SOX9 axis could be a target for 
the treatment of OA. In this case, the application of anti-miR-495 
to patients with OA could be an excellent strategy to restore 
SOX9 expression through the inhibition of miRNA-495.
DISCUSSION
Many risk factors influence OA or chondrocyte homeostasis, 
and miRNAs are one of the risk factors that contribute to carti-
lage-related diseases, including OA.22 Accumulating evidence 
has shed light on the roles of miRNAs in OA pathogenesis and 
chondrocyte homeostasis.23 The current study evaluated the 
potential of anti-miR-495 as a therapeutic molecule in an in vi-
tro OA environment. Our previous finding that miRNA-495 tar-
gets SOX9 to inhibit the chondrogenic differentiation of human 
MSCs12 presented us with the idea that rescuing SOX9 expres-
sion by anti-miR-495 might be helpful as a therapeutic strategy 
for OA pathogenesis. SOX9 is known to repress chondrocyte hy-
pertrophy and osteogenesis, thereby promoting chondrogene-
sis.24,25 In cartilage tissues with OA, progenitor cells fail to regen-
erate intact cartilage in the damaged sites,26,27 and decreased 
SOX9 levels may be one of the causes.28 Some studies have sup-
ported the importance of SOX9 in OA therapy to restore chon-
drocyte function, as well as to secrete COL2A1 and proteogly-
cans.29-31 In addition, lentivirus-mediated overexpression of 
SOX9 can downregulate the levels of some catabolic proteins, 
including MMP13 and ADAMTS5.32 Thus, maintaining or rein-
forcing SOX9 expression in chondrocytes can be a very impor-
tant therapeutic approach for regenerating cartilage tissue or 
delaying OA progression. We also showed that inhibition of 
miRNA-495, a potential repressor of SOX9, prevented the loss 
of SOX9 expression in IL-1β-treated TC28a2 chondrocytes, in-
dicating that anti-miR-495, which functions as an enhancer of 
SOX9 expression in OA chondrocytes, could be employed in 
the development of miRNA-based drugs. CCL4 has also been 
reported as a target mRNA for miRNA-495 in chondrocytes.14 
For this reason, we expected that transfection of anti-miR-495 
with chondrocytes (TC28a2 cell line) would upregulate the ex-
pression levels of CCL4 mRNA. However, anti-miR-495 reduced 
the mRNA expression levels of CCL4 in an inflammatory envi-
ronment. The reason may be due to anti-miR-495-mediated up-
regulation of SOX9 expression. A recent report showed that 
SOX9 overexpression alleviates IL-1β-induced inflammatory 
responses in human chondrocytes,31 which means that SOX9 
upregulation by anti-miR-495 inhibited the IL-1β-induced 
CCL4 expression in chondrocytes. Under the IL-1β-mediated 
inflammatory condition, siRNA-mediated knockdown of SOX9 
rescued the protein levels of CCL4 reduced by anti-miR-495 
(Fig. 4D), which support our hypothesis that the anti-miR-
495-mediated upregulation of SOX9 expression might inhibit 
CCL4 expression in chondrocytes. Therefore, we suggest that 
SOX9, rather than CCL4, is more strongly correlated with miR-
NA-495, especially in IL-1β-induced inflammation.
Research has shown that miRNA-495 has multiple functions 
in maintaining the homeostasis of various cells and that it plays 
a role in various diseases. The role of miRNA-495 in bone ho-
meostasis remains controversial. A previous study showed that 
miRNA-495 inhibits new bone regeneration by targeting the 
high mobility group AT-Hook 2 and that anti-miR-495 enhanc-
es femur healing in murine experimental models.33 However, a 
recent study reported a contradictory result showing that miR-
NA-495 could promote the proliferation and differentiation of 
osteoblasts in mice with tibial fracture.34 These conflicting re-
sults may be due to the age of the experimental animals or dif-
ferent experimental conditions. In addition, inhibition of miR-
NA-495 has been found to enhance the therapeutic efficacy of 
angiogenesis in human induced pluripotent stem cells.35 Thus, 
miR-495 can be considered as a potential therapeutic target for 
treating skeletal and angiogenesis-related diseases. Neverthe-
less, the development of miRNA-495-based drugs still faces 
many obstacles for its clinical application, since miRNA-495 
may also act as a tumor suppressor.36 While a few studies have 
shown that the expression of miRNA-495 is upregulated in he-
patocellular carcinoma37 and breast cancer stem cells,38 in which 
it positively regulates cell proliferation and invasion, thereby 
promoting tumor progression, miRNA-495 has also been de-
scribed as a tumor suppressor in many other related studies. 
miRNA-495-mediated inhibition of cell proliferation and inva-
sion has been detected in different types of cancer, including 
glioblastoma multiforme39 and myeloid leukemia.40 Thus, identi-
fying the universal role of miRNA-495 in tumors remains con-
troversial, and the reasons why miRNA-495 is either up- or 
downregulated in different types of cancers also remains un-
clear. Accordingly, at the moment, it may be too early to devel-
op miRNA-495-based drugs, either as an injectable drug or as 
an oral drug, and the development of drugs targeting miR-
NA-495 would require consideration of many risk factors. De-
spite these risk factors in other diseases, we aimed to determine 
whether miRNA-495 could be a therapeutic target for the treat-
ment of OA. Since, unlike most tissues, articular cartilage has no 
blood vessels, nerves, or lymphatics, targeting miRNA-495 in the 
local area with small cartilage defects would minimize unex-
pected side effects. 
Although we found that miR-495 could be a target for OA 
treatment in human cells and tissues obtained from patients 
with OA, there are some limitations to the current study. For 
example, we could not conclude the role of anti-miR-495 in an-
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imal models with OA, which is a weakness of this study. Recent 
studies have reported a therapeutic effect for anti-miRs in ani-
mal cartilage tissue with OA: The intra-articular injection of an-
ti-miR-34a alleviated OA progression in a rat experimental 
model of OA.41 A miR-146a inhibitor improved the destruction 
of articular cartilage in surgically induced OA mice.42 Intra-ar-
ticular injection of antago-miR-483-5p reportedly delayed the 
progression of experimental OA.43 These results highlight the 
potential of anti-miRs as novel OA gene therapeutics through 
inhibition of miRNAs associated with OA pathogenesis. These 
studies used the lentivirus system as a delivery system for anti-
miRs. However, there are still many questions and consider-
ations regarding the use of lentivirus for clinical purposes.44 As 
anti-miR delivery to cartilage tissue by intra-articular adminis-
tration may serve as a powerful strategy for OA treatment, an 
ideal vector system for transducing genes into hard tissues, 
such as cartilage, should be considered before clinical applica-
tion. Although this study did not show the therapeutic effect of 
anti-miR-495 in animal models with OA, we believe that the re-
sults contain important experimental results that can be applied 
to humans, since our study is the first to show that miR-495 
can be a target for OA treatment using human cells and patient 
samples. Overall, we believe this information will help lay the 
basis for future in vivo experiments.
Taken together, we found that miRNA-495 is upregulated in 
normal human chondrocyte cells (TC28a2 cells) treated with 
IL-1β and in primary chondrocytes obtained from the damaged 
cartilage tissues of patients with OA. Applying anti-miR-495 to 
inhibit miRNA-495 prevented the loss of the expression of SOX9 
and COL2A1, which are key markers of chondrocytes. Thus, we 
suggest that local application of anti-miR-495 to damaged carti-
lage tissues could be a novel therapeutic strategy through which 
to prevent OA progression. In future studies, the use of an ap-
propriate experimental animal model of OA will be necessary 
to evaluate whether local administration of anti-miR-495 is ef-
fective in preventing the progression of OA. 
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